Solesence generated $13.0 million in revenue for the quarter ended March 31, 2026, down from $14.6 million in the same period of 2025. Gross profit totaled $3.3 million, lifting gross margin to 26% from 23%, while the company recorded a net loss of $0.8 million compared with net income of $0.08 million a year earlier.

Launched at the end of 2025, the Transform & Transcend initiative centers on operational excellence and new technology commercialization. Early efforts include leveraging intellectual property, expanding the addressable market and evolving the service model to capture greater value across the health care and beauty solution chain.

First-quarter investments in employee training and organizational restructuring created near-term profitability pressure but delivered improved efficiency and reduced labor costs. These operational enhancements aim to support sustainable margin expansion and position the company for stronger financial performance in subsequent quarters.

Solesence expanded its over‐the‐counter product claims through commercialization of WHSPR™ and Chromalüm™ platform technologies and strengthened its board with the addition of financial executive Marc James as an independent director.